Loading company…
Mablink Bioscience develops antibody-drug conjugate therapies using its PSARlink platform.
Founded in 2018 and based in Lyon, Mablink Bioscience develops cancer therapies using PSARlink™, its patented antibody-drug conjugate platform. The technology uses hydrophilic drug linkers to improve pharmacological properties. In April 2021, the company raised EUR 4 million (USD 4.83 million) in Seed funding from Elaia Partners, Groupe Crédit Agricole and Simba Santé.
Funding rounds, investors and people for this company come from licensed data. A free account shows the first rows of each section; an approved contribution opens every profile in full.
Sign in